دورية أكاديمية
Bone marrow microRNA-34a is a good indicator for response to treatment in acute myeloid leukemia.
| العنوان: | Bone marrow microRNA-34a is a good indicator for response to treatment in acute myeloid leukemia. |
|---|---|
| المؤلفون: | Abdellateif MS; Department of Cancer Biology, Medical Biochemistry and Molecular Biology, National Cancer Institute, Cairo University, Cairo, 11976, Egypt., Hassan NM; Department of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, 11976, Egypt., Kamel MM; Department of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, 11976, Egypt., El-Meligui YM; Department of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, 11976, Egypt. |
| المصدر: | Oncology research [Oncol Res] 2024 Feb 06; Vol. 32 (3), pp. 577-584. Date of Electronic Publication: 2024 Feb 06 (Print Publication: 2024). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Tech Science Press Country of Publication: United States NLM ID: 9208097 Publication Model: eCollection Cited Medium: Internet ISSN: 1555-3906 (Electronic) Linking ISSN: 09650407 NLM ISO Abbreviation: Oncol Res Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2021- : Henderson, NV : Tech Science Press Original Publication: New York : Pergamon Press, c1992- |
| مواضيع طبية MeSH: | MicroRNAs* , Leukemia, Myeloid, Acute*/diagnosis , Leukemia, Myeloid, Acute*/genetics , Leukemia, Myeloid, Acute*/metabolism, Humans ; Bone Marrow/chemistry ; Bone Marrow/metabolism ; Prognosis ; Disease-Free Survival |
| مستخلص: | Background: microRNA-34a (miR-34a) had been reported to have a diagnostic role in acute myeloid leukemia (AML). However, its value in the bone marrow (BM) of AML patients, in addition to its role in response to therapy is still unclear. The current study was designed to assess the diagnostic, prognostic, and predictive significance of miR-34a in the BM of AML patients. Methods: The miR-34a was assessed in BM aspirate of 82 AML patients in relation to 12 normal control subjects using qRT-PCR. The data were assessed for correlation with the relevant clinical criteria, response to therapy, disease-free survival (DFS), and overall survival (OS) rates. Results: miR-34a was significantly downregulated in AML patients [0.005 (3.3 × 10 -6 -1.32)], compared to the control subjects [0.108 (3.2 × 10 -4 -1.64), p = 0.021 ]. The median relative quantification (RQ) of miR-34a was 0.106 (range; 0-32.12). The specificity, sensitivity, and area under the curve (AUC) for the diagnosis of AML were ( 58.3% , 69.5% , 0.707 , respectively, p = 0.021 ). patients with upregulated miR-34a showed decreased platelets count <34.5 × 10 9 /L, and achieved early complete remission ( CR, p = 0.031 , p = 0.044 , respectively ) . Similarly, patients who were refractory to therapy showed decreased miR-34a levels in comparison to those who achieved CR [0.002 (0-0.01) and 0.12 (0-32.12), respectively, p = 0.002 ]. Therefore, miR-34a could significantly identify patients with CR with a specificity of 75% and sensitivity of 100% at a cut-off of 0.014 (AUC = 0.927, p = 0.005). There was no considerable association between miR-34a expression and survival rates of the included AML patients. Conclusion: miR-34a could be a beneficial diagnostic biomarker for AML patients. In addition, it serves as a good indicator for response to therapy, which could possibly identify patients who are refractory to treatment with 100% sensitivity and 75% specificity. Competing Interests: All authors declare that there is no conflict of interest. (© 2024 Abdellateif et al.) |
| References: | Eur Rev Med Pharmacol Sci. 2016 Jul;20(13):2878-83. (PMID: 27424989) Mol Med Rep. 2014 Apr;9(4):1283-8. (PMID: 24504520) Diagn Pathol. 2014 Mar 29;9:76. (PMID: 24678958) Cell Signal. 2015 Mar;27(3):443-52. (PMID: 25499621) Eur Rev Med Pharmacol Sci. 2015 Dec;19(24):4841-50. (PMID: 26744876) Nature. 2010 Oct 21;467(7318):986-90. (PMID: 20962848) Cancer Lett. 2017 Mar 1;388:96-106. (PMID: 27919789) Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020 Apr;28(2):476-483. (PMID: 32319382) Biomed Mater. 2021 Aug 04;16(5):. (PMID: 34280914) Biomed Pharmacother. 2019 Jan;109:1793-1801. (PMID: 30551433) Blood. 2017 Jan 26;129(4):424-447. (PMID: 27895058) Methods. 2001 Dec;25(4):402-8. (PMID: 11846609) Clin Lab. 2020 Mar 1;66(3):. (PMID: 32162890) Cancer Res. 2016 Feb 15;76(4):927-39. (PMID: 26676753) Oncotarget. 2014 Feb 28;5(4):872-81. (PMID: 24657911) Leukemia. 2013 Feb;27(2):353-61. (PMID: 22810507) Exp Hematol Oncol. 2016 Feb 03;5:4. (PMID: 26848406) Cell Death Dis. 2014 Jul 17;5:e1327. (PMID: 25032850) Blood. 2010 Dec 16;116(25):5638-49. (PMID: 20889924) Cancer Biomark. 2018;22(4):799-805. (PMID: 29945348) Cell Physiol Biochem. 2015;35(6):2192-202. (PMID: 25896587) Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Jun;27(3):790-795. (PMID: 31204933) Biomed Pharmacother. 2020 May;125:109878. (PMID: 32006898) Clin Lymphoma Myeloma Leuk. 2017 Feb;17(2):126-132.e1. (PMID: 27836483) J Natl Compr Canc Netw. 2019 Jun 1;17(6):721-749. (PMID: 31200351) Clin Cancer Res. 2011 May 1;17(9):2712-24. (PMID: 21367750) Int J Biochem Cell Biol. 2020 Feb;119:105666. (PMID: 31830533) Diagn Pathol. 2015 Jul 17;10:109. (PMID: 26185105) Hematology Am Soc Hematol Educ Program. 2009;:385-95. (PMID: 20008224) Cancer Manag Res. 2021 May 05;13:3629-3637. (PMID: 33981162) Dig Dis Sci. 2014 May;59(5):958-67. (PMID: 24370784) Med Sci Monit. 2015 Nov 09;21:3427-33. (PMID: 26549593) Oncotarget. 2015 May 30;6(15):13149-63. (PMID: 25909221) Biochemistry (Mosc). 2010 Dec;75(13):1650-66. (PMID: 21417999) Blood. 2016 May 19;127(20):2375-90. (PMID: 26980727) Exp Hematol. 2018 Jun;62:1-6. (PMID: 29601851) Cancer Metastasis Rev. 2021 Sep;40(3):925-948. (PMID: 33959850) Br J Haematol. 2011 Mar;152(5):524-42. (PMID: 21314823) J Formos Med Assoc. 2016 Sep;115(9):801-6. (PMID: 26414667) CA Cancer J Clin. 2017 Jan;67(1):7-30. (PMID: 28055103) Cell. 2004 Jan 23;116(2):281-97. (PMID: 14744438) |
| فهرسة مساهمة: | Keywords: AML; Leukemia; miR-34a; microRNA |
| المشرفين على المادة: | 0 (MicroRNAs) |
| تواريخ الأحداث: | Date Created: 20240216 Date Completed: 20240219 Latest Revision: 20240219 |
| رمز التحديث: | 20240219 |
| مُعرف محوري في PubMed: | PMC10865737 |
| DOI: | 10.32604/or.2023.043026 |
| PMID: | 38361758 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1555-3906 |
|---|---|
| DOI: | 10.32604/or.2023.043026 |